Biogen is building a ‘ventures’ team to ‘keep early portfolio externalized’news2025-08-04T11:21:17+00:00August 4th, 2025|Endpoints News|
Sanofi buys China rights to Arrowhead’s lipid drug for $130M upfrontnews2025-08-01T14:47:28+00:00August 1st, 2025|Endpoints News|
Endpoints livestream: Is China’s biotech boom unstoppable?news2025-07-31T14:33:56+00:00July 31st, 2025|Endpoints News|
Teva expects to make Q3 decision on sale of API unit, CEO says news2025-07-30T19:32:59+00:00July 30th, 2025|Endpoints News|
KKR buys HealthCare Royalty Partners as firm deepens bet on life sciencesnews2025-07-30T14:39:38+00:00July 30th, 2025|Endpoints News|
Madrigal licenses preclinical GLP-1 from CSPC for $120M upfrontnews2025-07-30T11:01:25+00:00July 30th, 2025|Endpoints News|
Viridian inks Japan licensing deal as it seeks to rival Amgen’s Tepezzanews2025-07-30T08:00:56+00:00July 30th, 2025|Endpoints News|
Exclusive: Formation Bio licenses IMIDomics IBD drugnews2025-07-29T10:00:12+00:00July 29th, 2025|Endpoints News|
Bristol Myers sends five immunology assets to new $300M biotechnews2025-07-29T02:16:36+00:00July 29th, 2025|Endpoints News|
Adaptimmune to sell cell therapy assets, including Tecelra, and lay off more staffnews2025-07-28T15:27:42+00:00July 28th, 2025|Endpoints News|
